Sanofi (SNY) struck a collaboration and licensing agreement with ScionxBio to develop long-acting xRNA therapeutics by leveraging the latter's TERA platform, ScionxBio said Tuesday.
ScionxBio said it will lead activities up to in vivo validation stages, and Sanofi will then assume responsibility for remaining preclinical activities, studies, clinical development, manufacturing, and worldwide commercialization.
The company said the programs are focused on conditions where sustained protein expression is important for clinical effects.
Price: 40.66, Change: +1.09, Percent Change: +2.75
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments